Dishman Carbogen Amcis Q3FY26 Investor Presentation: Revenue Up 5.5% YoY
Dishman Carbogen Amcis reported Q3FY26 revenue of ₹7,198 million, a 5.5% YoY increase. CDMO revenue grew 6.7% to ₹6,297 million. 9MFY26 revenue rose 4.3% to ₹20,805 million. EBITDA margin for Q3FY26 was 15.7%, down from 20.5% YoY, while 9MFY26 margin improved to 19.4%.
The revenue growth and segment performance details are significant for investors. However, the decrease in EBITDA margin and deferred revenue temper the immediate positive impact.
While revenue showed a year-on-year increase, the EBITDA margin declined in Q3FY26 compared to the previous year. The deferral of revenue and one-time expenses also impact the overall financial picture.
Dishman Carbogen Amcis Limited has released its investor presentation for the third quarter ended December 31, 2025. The company reported a Net Revenue of ₹7,198 million for Q3FY26, marking a 5.5% year-on-year increase from ₹6,823 million in Q3FY25. This growth was primarily driven by higher revenue from the CDMO segment, which saw a 6.7% increase to ₹6,297 million compared to the previous year.
The Marketable Molecules (MM) segment revenue for Q3FY26 decreased by 2.4% to ₹901 million from ₹922 million in Q3FY25, mainly due to lower Quats revenue. However, for the nine months ended FY26 (9MFY26), Net Revenue stood at ₹20,805 million, a 4.3% increase from ₹19,952 million in 9MFY25, largely due to higher Cholesterol and Vitamin D analogues revenue contribution.
EBITDA for Q3FY26 was ₹1,131 million, with an EBITDA margin of 15.7%, a decrease from 20.5% in Q3FY25. This margin contraction was attributed to lower contributions from late Phase III molecules in the CDMO segment and a higher composition of cholesterol revenue in the MM segment. Conversely, for 9MFY26, EBITDA increased to ₹4,027 million with a margin of 19.4%, up from ₹3,163 million and 15.9% in 9MFY25, driven by improved margins in both CDMO and MM segments.
The company also noted that approximately ₹200 million (Rs. 20 crore) in supplies were deferred from Q3FY26 to Q4FY26 due to delayed intermediate supplies and holiday periods in Europe. Employee expenses included a one-time provision of approximately ₹33 million for severance pay and social insurance costs, and finance costs included a one-time expense of approximately ₹110 million for new syndication credit facilities.
What to do with a filing like this
Dishman Carbogen Amcis Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dishman Carbogen Amcis Limited. Read the original for the full detail.